ADVERTISEMENT
Cariprazine Effective Against ADT-resistant MDD
Patients with major depressive disorder (MDD) who have inadequate response to antidepressant treatment (ADT) could benefit from adjunctive treatment with cariprazine (CAR), according to new findings presented in a poster at Psych Congress 2022 in New Orleans, Louisiana. Cariprazine is a dopamine D3 preferring D3/D2 and serotonin 5HT1A receptor partial agonist.
The efficacy of CAR across a range of depressive symptoms was assessed by evaluating items of the Montgomery-Asberg Depression Rating Scale (MADRS) in outpatients from a phase 3 study from baseline to 6 weeks. Data from 1.5 mg/d CAR and ADT and 3.0 mg/d CAR and ADT were compared to data from a placebo (PBO) and ADT.
Related: Psilocybin Associated With Improved Symptoms in Treatment-Resistant Depression Patients
With 751 patients (502 on CAR and 249 on PBO), the LSMD (95% CI) score change from baseline to week 6 was significant in favor of CAR. Items of the MADRS scale were assessed individually over the course of the study, including apparent sadness, reported sadness, reduced appetite, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts, showing improvement compared to PBO.
Reference
Maletic, V, et al. Efficacy of Adjunctive Cariprazine Across Individual Depressive Symptoms in Major Depressive Disorder: A Post-Hoc Analysis. Poster presented at Psych Congress 2022; September 17-20, 2022.
